🇺🇸United States
High IRB/Ethics Committee Fees and Site Activation Delays
1 verified sources
Definition
IRB submissions and approvals incur non-refundable fees per protocol and site, compounded by lengthy review cycles that delay site activation. These administrative hurdles create recurring costs even if approval is not granted, with total site start-up reaching $30K-$200K.[2]
Key Findings
- Financial Impact: $1,000-$5,000+ per site IRB fee; $30,000-$200,000 total per site activation
- Frequency: Recurring per site and per new protocol
- Root Cause: Fragmented administrative processes, multiple revision cycles, and institutional fee structures
Why This Matters
This pain point represents a significant opportunity for B2B solutions targeting Biotechnology Research.
Affected Stakeholders
Site Investigators, IRB Coordinators, Sponsor Regulatory Teams, Contract Specialists
Action Plan
Run AI-powered research on this problem. Each action generates a detailed report with sources.
Methodology & Sources
Data collected via OSINT from regulatory filings, industry audits, and verified case studies.
Evidence Sources:
Related Business Risks
Protocol Approval Delays Driving Trial Start-Up Time Drag
$55,716 per day Phase III trial delay; ~$390,000 per delayed week per site
Excessive Protocol Amendments in Research Protocol Development
$250,000-$450,000 per amendment
Idle Resources from Protocol Amendment Cycle Times
$453,932 average per amendment implementation
High Development Costs and Funding Shortfalls
$Hundreds of millions per project in unrecouped development costs
Civil Money Penalties for ClinicalTrials.gov Non-Compliance in Biotech Trials
$10,000 per day per violation
Publish-or-Perish Conflicts with Patent Timing
$Reduced royalties over shortened patent life (estimable in millions for successful drugs)